Janssen's Amivantamab Subcutaneous Injection Receives NMPA Approval in China for EGFR-Mutated Advanced NSCLC

Gelonghui December 25th | Johnson & Johnson announced that its innovative therapeutic drug Riketra® – Amivantamab Injection (Subcutaneous Injection) has officially received approval from the National Medical Products Administration (NMPA) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations.